Nature's Way Esberitox 100 Chews
Nature's Way Esberitox is a supercharged echinacea formula to help you strengthen your immune system and feel better faster when you're feeling an illness coming on.
Nature's Way Esberitox Highlights & Benefits
- Supercharged Echinacea for an Immune System Boost
- Fell Better Faster When Ill
- Powerful Immune Support
- This Formula Has Been Used in Europe for Over 90 Years
- In Clinical Studies People Responded Better After Taking Esberitox
Take 6 tablets three times daily initially for faster results. Reduce to 4 tablets three times daily as you begin to feel better. Adults: 4-6 tablets, 3 times daily. Children over 12 years: 4-6 tablets, 3 times daily. Age 7-11 years: 2-3 tablets, 3 times daily. Age 4-6 years: 1-2 tablets, 3 times daily.
Nature's Way Esberitox 100 Chews Ingredients & Supplement Facts
Warnings & Side Effects
Not recommended for children under 4 years of age or individuals with autoimmune diseases, HIV infection, progressive systemic disease, or who are taking cytostatic or immunosuppressive therapy. Nursing women or individuals who are allergic to Echinacea or other flowers in the Compositae (Asteraceae) family, or any of the other ingredients of Esberitox®, should not use this product. If you are pregnant or taking any medications, consult a healthcare professional before use. Hypersensitivity, gastrointestinal discomfort, or dizziness may occur. If you observe these or other side effects, discontinue use and consult a healthcare professional.
Keep out of reach of children.
Fabara AN, Fraaije MW. An overview of microbial indigo-forming enzymes. Appl Microbiol Biotechnol. 2020 Feb;104(3):925-933. doi: 10.1007/s00253-019-10292-5. Epub 2019 Dec 13. PMID: 31834440; PMCID: PMC6962290.
Uchiyama K, Takami S, Suzuki H, Umeki K, Mochizuki S, Kakinoki N, Iwamoto J, Hoshino Y, Omori J, Fujimori S, Yanaka A, Mizokami Y, Ohkusa T. Efficacy and safety of short-term therapy with indigo naturalis for ulcerative colitis: An investigator-initiated multicenter double-blind clinical trial. PLoS One. 2020 Nov 5;15(11):e0241337. doi: 10.1371/journal.pone.0241337. PMID: 33151988; PMCID: PMC7644062.